source
- Roche-MediLink’s B7-H3 ADC meets primary endpoint in phase 3 SCLC trial, median survival 13.3 monthsRoche and its partner MediLink reported phase 3 results for the B7-H3-directed antibody-drug conjugate (ADC) in small-cell lung cancer. The trial met its primary endpoint, with a median overall sur…
- Definium says its LSD drug notched another Phase 3 win in anxiety disorderDefinium Therapeutics reported results Monday for its third Phase 3 readout this year on its oral LSD candidate, called DT120, and is gearing up for an FDA submission. The company’s late-stage data…Endpoints · 22m ago↗ source